Last reviewed · How we verify
NCT04019847: STAK
STAK Tool for Treatment of Arthrofibrosis Post Total Knee Replacement
NA trial testing STAK Tool in Arthrofibrosis in 35 participants. Completed in 19 August 2019.
19 August 2019
Quick facts
| Lead sponsor | University Hospitals, Leicester |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 2 August 2017 |
| Primary completion | 19 August 2019 |
| Estimated completion | 19 August 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- STAK Tool
- Standard treatment
Conditions studied
- Arthrofibrosis — all drugs for Arthrofibrosis →
Sponsor
University Hospitals, Leicester
Who can join
Adults 18 to 95, any sex, with Arthrofibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A common complication following total knee replacement (TKR) is arthrofibrosis, a severe stiffening of the knee caused by scar tissue. The aims of this mixed methods feasibility study are to (1) record the effect of use of the STAK Tool on knee flexion active range of movement (KROM) immediately following 8 weeks use and 6 months following use, (2) explore patients' experiences of arthrofibrosis and use of the STAK Tool, (3) Consider appropriate outcome measures (e.g. KROM, patient experience/acceptability, The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Oxford Knee Score (OKS) and other clinical measures and (4) design a protocol to evaluate the effectiveness of the STAK Tool.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The STAK tool: evaluation of a new device to treat arthrofibrosis and poor range of movement following total knee arthroplasty and major knee surgery.
Aspinall SK, Wheeler PC, Godsiff SP, Hignett SM, et al · · 2020 · cited 3× · PMID 33215140 · DOI 10.1302/2633-1462.18.bjo-2020-0096
Verify or expand the search:
- PubMed search for NCT04019847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospitals, Leicester trials
Trials by the same sponsor.
- NCT06179771 — Pilot Study on HA380 Column Use in Critically Ill Patients Receiving Extracorporeal Support. · NA · recruiting
- NCT06269172 — Perceptions Across Ethnicities to Develop an Adapted Intervention for Breathlessness · unknown
- NCT06152406 — Ablate and Pace HIS Study · NA · recruiting
- NCT06523192 — Validation of the English Version of the Drug Hypersensitivity Quality of Life Questionnaire · completed
- NCT06025422 — In-shoe Pressures Associated With Footwear Fit Guidelines · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04019847 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals, Leicester
- Last refreshed: 28 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04019847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing